Adherence to Gastro-protection in Non-steroidal Anti-inflammatory Drug (NSAID) Using Patients

AstraZeneca2,000 enrolled

Overview

Prospective multicentric study to evaluate the compliance of gastroprotective treatment in NSAID patients at risk of GI complications. Secondary objectives: To identify the factors associated to treatment compliance (both NSAID and PPI), to evaluate the relationship between compliance and NSAID-associated GI events

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

Compliance Gastroprotector Therapy Risk Factors

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Patients consulting to the specialized care clinics who have been prescribed NSAID and gastroprotection for at least 15 days following standard clinical practice. Exclusion Criteria: * Any gastroprotective treatment prescribed for other condition than NSAID-related gastrointestinal event prevention

Locations (128)

Outcomes

Primary Outcomes

Adherence to gastroprotection treatment

Time frame: End of follow-up (3-5 weeks)

Secondary Outcomes

Identify factors associated with treatment compliance

Time frame: End of follow-up

Evaluate the relationship among GI events and treatment compliance

Time frame: End of follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Vitoria-Gasteiz, Alava, Spain

Research Site

Albacete, Albacete, Spain

Research Site

Alacant / Alicante, Alicante, Spain

Research Site

Alcoy, Alicante, Spain

Research Site

Elda, Alicante, Spain

Research Site

Elx / Elche, Alicante, Spain

Research Site

La/villajoyosa Vila Joiosa, Alicante, Spain

Research Site

Orihuela, Alicante, Spain

Research Site

San Bartolomé, Alicante, Spain

Research Site

San Vicent del Raspeig, Alicante, Spain

...and 118 more locations